SCHEMBL5680950

SCHEMBL5680950

C1CNCC(C2CCNCC2)C1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC6A1 P30531 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
SLC6A11 P48066 1/20 0.38
TSHR P16473 1/20 0.38
LMNA P02545 1/20 0.38
SLC6A13 Q9NSD5 1/20 0.38
APLNR P35414 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
ATM Q13315 1/20 0.37
NOS2 P35228 1/20 0.37
CYP2D6 P10635 1/20 0.37
ALDH1A1 P00352 2/20 0.35
CXCR4 P61073 1/20 0.33
CCR5 P51681 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL433659 0.95 SLC6A1 (0.41) SLC6A1SMN1; SMN2SLC6A11TSHRLMNA
SCHEMBL6581856 0.95 SLC6A1 (0.41) SLC6A1SMN1; SMN2SLC6A11TSHRLMNA
SCHEMBL21324676 0.92 ALDH1A1 (0.40) SLC6A1SMN1; SMN2SLC6A11TSHRLMNA
SCHEMBL20156421 0.92 ALDH1A1 (0.40) SLC6A1SMN1; SMN2SLC6A11TSHRLMNA
SCHEMBL9115694 0.90 ALDH1A1 (0.38) SLC6A1SMN1; SMN2SLC6A11TSHRLMNA
SCHEMBL24912524 0.89 ALDH1A1 (0.47) SLC6A1SMN1; SMN2SLC6A11TSHRLMNA
SCHEMBL6426932 0.89 ALDH1A1 (0.47) SLC6A1SMN1; SMN2SLC6A11TSHRLMNA
SCHEMBL791582 0.89
SCHEMBL22540086 0.89 ALDH1A1 (0.47) SLC6A1SMN1; SMN2SLC6A11TSHRLMNA
SCHEMBL16877745 0.89

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4504338-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF RAPT Therapeutics, Inc. (US) 2025-02-12 EP disclosed
WO-2023196432-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF RAPT THERAPEUTICS, INC. (US) 2023-10-12 WO disclosed
CN-116102543-A GLP-1R agonist, synthesis method and application thereof 江南大学 2023-05-12 CN disclosed
EP-3941459-A1 QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF Stingray Therapeutics, Inc. (US) 2022-01-26 EP disclosed
CN-113924092-A Quinoline and quinazoline compounds and methods of use thereof 斯汀格瑞治疗股份有限公司 2022-01-11 CN disclosed
CN-108250128-A Compound as potassium channel modulating agents 江苏先声药业有限公司 2018-07-06 CN disclosed
CN-103694163-A Compounds as Potassium Channel Modulators SHANGHAI SIMCERE DRUG RES CO LTD 2014-04-02 CN disclosed
EP-1060785-B1 Interfacially polymerized, bipiperidine-polyamide membranes for reverse osmosis and/or nanofiltration and process for making the same HYDRANAUTICS (US) 2006-04-05 EP disclosed
EP-1339691-A1 NOVEL COMPOUNDS GlaxoSmithKline S.p.A. (IT) 2003-09-03 EP disclosed
CN-1439004-A Indole derivatives for the treatment of central nervous system disorders LUNDBECK & CO AS H (DK) 2003-08-27 CN disclosed
US-6464873-B1 POLYFUNCTIONAL AROMATIC OR CYCLOALIPHATIC ACYL HALIDE REACTANT; HIGH FLUX RATES AND LOW PRESSURES WITH HIGH SULFATE REJECTION. HYDRANAUTICS 2002-10-15 US disclosed
WO-2002044154-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE SPA (IT) 2002-06-06 WO disclosed
EP-1060785-A1 Interfacially polymerized, bipiperidine-polyamide membranes for reverse osmosis and/or nanofiltration and process for making the same HYDRANAUTICS (US) 2000-12-20 EP disclosed
US-5215967-A AMINOACID DERIVATIVES INHIBITING RENIN MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1993-06-01 US disclosed